FR2986537B1 - Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales - Google Patents

Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales

Info

Publication number
FR2986537B1
FR2986537B1 FR1251120A FR1251120A FR2986537B1 FR 2986537 B1 FR2986537 B1 FR 2986537B1 FR 1251120 A FR1251120 A FR 1251120A FR 1251120 A FR1251120 A FR 1251120A FR 2986537 B1 FR2986537 B1 FR 2986537B1
Authority
FR
France
Prior art keywords
functionality
stem cells
epithelial stem
keratin material
apt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1251120A
Other languages
English (en)
Other versions
FR2986537A1 (fr
Inventor
Bruno Bernard
Josserand Michelle Rathman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1251120A priority Critical patent/FR2986537B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Priority to CN201380008401.5A priority patent/CN104094117B/zh
Priority to ES13702650.6T priority patent/ES2569711T3/es
Priority to US14/378,415 priority patent/US9658212B2/en
Priority to EP13702650.6A priority patent/EP2812689B1/fr
Priority to PCT/EP2013/052375 priority patent/WO2013117618A1/fr
Priority to JP2014556043A priority patent/JP6184984B2/ja
Priority to BR112014019378-9A priority patent/BR112014019378B1/pt
Publication of FR2986537A1 publication Critical patent/FR2986537A1/fr
Application granted granted Critical
Publication of FR2986537B1 publication Critical patent/FR2986537B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé d'évaluation in vitro d'au moins un actif apte à préserver la fonctionnalité des cellules souches épithéliales, en particulier à maintenir ou stimuler la croissance et/ou la densité et/ou le renouvellement d'une matière kératinique, consistant à déterminer la faculté de l' (des) actif(s) à mimer un état hypoxique dans la matière kératinique, le (les) actif(s) étant apte(s) à augmenter l'expression d'au moins l'anhydrase carbonique IX en tant que marqueur biologique de l'hypoxie, dans la matière kératinique traitée avec le (les) actif(s) comparativement à la matière kératinique non traité par le (les) actif(s). Elle concerne également l'utilisation d'un tel procédé.
FR1251120A 2012-02-07 2012-02-07 Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales Expired - Fee Related FR2986537B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1251120A FR2986537B1 (fr) 2012-02-07 2012-02-07 Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales
ES13702650.6T ES2569711T3 (es) 2012-02-07 2013-02-07 Procedimiento para evaluar un agente o agentes activos capaces de conservar la funcionalidad de células madre epiteliales
US14/378,415 US9658212B2 (en) 2012-02-07 2013-02-07 Process for evaluating active agent(s) capable of preserving the functionality of epithelial stem cells
EP13702650.6A EP2812689B1 (fr) 2012-02-07 2013-02-07 Processus pour évaluer un agent actif ou des agents actifs capables de préserver la fonctionnalité de cellules souches épithéliales
CN201380008401.5A CN104094117B (zh) 2012-02-07 2013-02-07 用于评估能够保持上皮干细胞的功能的活性剂的方法
PCT/EP2013/052375 WO2013117618A1 (fr) 2012-02-07 2013-02-07 Processus pour évaluer un agent actif ou des agents actifs capables de préserver la fonctionnalité de cellules souches épithéliales
JP2014556043A JP6184984B2 (ja) 2012-02-07 2013-02-07 上皮幹細胞の機能性を保存可能な活性物質の評価方法
BR112014019378-9A BR112014019378B1 (pt) 2012-02-07 2013-02-07 Processo in vitro de avaliação de pelo menos um agente ativo e uso de um processo de avaliação

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1251120A FR2986537B1 (fr) 2012-02-07 2012-02-07 Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales

Publications (2)

Publication Number Publication Date
FR2986537A1 FR2986537A1 (fr) 2013-08-09
FR2986537B1 true FR2986537B1 (fr) 2014-03-28

Family

ID=45926801

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1251120A Expired - Fee Related FR2986537B1 (fr) 2012-02-07 2012-02-07 Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales

Country Status (8)

Country Link
US (1) US9658212B2 (fr)
EP (1) EP2812689B1 (fr)
JP (1) JP6184984B2 (fr)
CN (1) CN104094117B (fr)
BR (1) BR112014019378B1 (fr)
ES (1) ES2569711T3 (fr)
FR (1) FR2986537B1 (fr)
WO (1) WO2013117618A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3391048B1 (fr) * 2015-12-15 2021-07-07 Case Western Reserve University Évaluation de carcinome épidermoïde buccal à l'aide de la bêta-défensine
KR102463174B1 (ko) * 2017-07-31 2022-11-04 삼성전자주식회사 재설정 가능한 증폭기 및 그 증폭 방법
FR3094640B1 (fr) * 2019-04-08 2021-11-12 Oreal Procédé de traitement cosmétique des cheveux comprenant l’application d’une composition lavante comprenant des polymères amphotères puis d’une composition de soin comprenant des agents antichute et des polysaccharides anioniques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146964A1 (en) * 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
US20060084123A1 (en) * 2001-12-13 2006-04-20 Harris Adrian L MN and hypoxia
FR2838336B1 (fr) 2002-04-11 2005-06-03 Utilisation d'un derive pyridine-dicarboxylate ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
MY154677A (en) * 2006-03-07 2015-07-15 Shroff Geeta Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
CN101508975A (zh) * 2009-03-26 2009-08-19 大连理工大学 一种低氧条件下微囊化成骨细胞支持和调控造血干/祖细胞体外扩增的方法
CN101792737A (zh) * 2010-03-24 2010-08-04 晏泽 低氧间充质干细胞的培养方法、用途及组合制剂
EP2404500A1 (fr) * 2010-07-07 2012-01-11 Universite Pierre Et Marie Curie - Paris 6 Animal transgénique en tant que modèle pour identifier des cellules souches adultes et leurs utilisations
ITMI20130554A1 (it) * 2013-04-09 2014-10-10 Giuliani Spa Composizione farmaceutica o cosmetica atta a preservare le cellule staminali epiteliali

Also Published As

Publication number Publication date
JP6184984B2 (ja) 2017-08-23
JP2015511127A (ja) 2015-04-16
EP2812689A1 (fr) 2014-12-17
FR2986537A1 (fr) 2013-08-09
US20160018388A1 (en) 2016-01-21
CN104094117A (zh) 2014-10-08
BR112014019378A8 (pt) 2017-07-11
BR112014019378B1 (pt) 2022-04-12
EP2812689B1 (fr) 2016-02-03
WO2013117618A1 (fr) 2013-08-15
ES2569711T3 (es) 2016-05-12
US9658212B2 (en) 2017-05-23
CN104094117B (zh) 2016-08-24
BR112014019378A2 (fr) 2017-06-20

Similar Documents

Publication Publication Date Title
MA35431B1 (fr) Composition antiparasitaires comprenant un agent actif d'isoxazoline procedes et utilisations associes
AR109260A2 (es) Secuencias de nucleótidos que codifican proteínas insecticidas
SV2007002813A (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
BR112014017158A2 (pt) aberturas tratadas
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
PE20120536A1 (es) Combinacion de un agente fungicida sintetico y bacillus subtilis qst 173 para el control de hongos fitopatogenos
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
FR3038324B1 (fr) Procede de cryoconservation de cellules a visee therapeutique
CL2011002905A1 (es) Metodos para analizar la sensibilidad celular a farmacos que comprende obtener muestras de pacientes, combinar a lo menos 35 de las alicuotas con una composicion de farmaco y medir apoptosis o agotamiento celular en por lo menos una poblacion de celulas en cada una de las por lo menos 35 alicuotas; dispositivo para analizar dicha sensibilidad.
TR201911270T4 (tr) Polimerik mirsen bileşimleri.
MX366369B (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
FR2986537B1 (fr) Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales
AR061148A1 (es) Manipulacion del metabolismo del nitrogeno
CL2018000227A1 (es) Proteínas inhibidoras de insectos novedosas
UY37567A (es) Proteínas toxinas pesticidas activas contra insectos lepidópteros
EA200901043A1 (ru) Композиция для улучшения жизнеспособности растений
BRPI0507959A (pt) uso de inibidores e moduladores de tweak para o tratamento de condições neurológicas
EA201690719A1 (ru) Композиции гербицидов и защитных средств, содержащие амиды n-(1,3,4-оксадиазол-2-ил)арилкарбоновой кислоты
EA200901061A1 (ru) Фармацевтические и косметические композиции для ускорения процесса заживления ран и других поверхностных повреждений
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
BR112012005194A2 (pt) uso de éteres de glicerol como agentes de ativação de efeitos biológicos de ao menos uma substância herbicida, fungicida ou inseticida , composição fitossanitária e processo de tratamento fitossanitário
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
ECSP10010720A (es) Nuevas posibilidades de lucha contra la giardiasis
TR200904029A2 (tr) Bir biyomalzeme.
CL2009000986A1 (es) Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20211005